Explore the Agenda
8:00 am Morning Check in & Coffee
8:45 am Chair’s Opening Remarks
Transforming Patient Care Through Understanding Disease Complexity & Heterogeneity
9:00 am Targeted PDE4 Inhibition Using PALI-2108 Prodrug as a Novel Therapeutic Strategy in Fibrostenotic Crohn’s Disease
- Highlighting how gut-restricted pharmacology and translational biomarker science are converging to redefine the treatment of fibrostenotic IBD
9:30 am Unlocking the Power of Clinical Phenotypes to Advance Precision Medicine Targets
- Highlighting stable, well-established features, such as ileal and colonic Crohn’s disease, that correlate with treatment outcomes and complication risk
- Demonstrating how clinical phenotypes could guide patient stratification in clinical trials, identify subpopulations most likely to respond, and optimize therapy selection
- Discussing why precision medicine approaches in IBD have lagged behind oncology, and how aligning research priorities with commercial feasibility can help advance targeted therapies
10:00 am Roundtable Discussion: Advancing Patient Outcomes by Addressing Heterogeneity in Crohn’s Disease & Ulcerative Colitis
- Clinical complexity of Crohn’s Disease including fibrostenosis, fistula formation, and inflammation independent complications
- Limitations of current therapies that control inflammation but fail to resolve fibrosis or tissue damage
- Exploring unmet needs and future therapeutics from a clinicians perspective
10:30 am Morning Break & Networking
Unlocking Drug Discovery Insights Through Omics and AI in Complex Gut Disease Models
11:30 am Innovative Multiomics Strategies to Accelerate Drug Development and Decode Disease Mechanisms
- Discover how molecular signatures across disease phenotypes inform drug response and resistance, with applications beyond primary indications
- Learn how tissue mass spectrometry and long-read sequencing offer deeper insights into disease biology and overcome limitations of traditional short-read approaches
- Explore innovative multiomics frameworks that reveal hidden patterns in unstable and fibrotic disease states, enabling more precise therapeutic development
12:00 pm Harnessing Multiomics and Machine Learning to Overcome Metadata Challenges and Build Predictive Biomarker Signatures
- Address logistical and analytical challenges in metadata capture to ensure robust, reproducible linkage between omics data and clinical outcomes
- Discuss how multiomic integration can reflect IBD’s molecular complexity and drive more accurate biomarker discover
- Learn how machine learning approaches can integrate multiomic datasets to identify composite
12:30 pm Lunch Break & Networking
1:30 pm Redefining Success in IBD Clinical Trials by Investigating Mechanism of Therapeutic Response/Non-Response & Driving Innovation
- Highlight the limitations of existing treatments in achieving full remission
- Show how residual disease activity leads to complications like fibrosis, fistulas, and surgery
- Explore how precision endpoints and biomarker-guided trials can improve therapeutic targeting
Transforming Clinical Trial Formation through Wider Data Collaboration, Biomarker Guidance & Targeted Endpoints
2:00 pm Roundtable Discussion: Delivering Faster & More Reliable IBD Trials by Redefining Recruitment Strategies
- Explore innovative recruitment and retention strategies that have successfully reduced trial delays
- Discuss methods to minimize placebo variability and enhance statistical confidence. How are different teams approaching this challenge?
- Share experiences using real-world data and predictive tools to identify ideal candidates, what impact has this had on response rates and trial costs?